iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression

iTolerance, Inc. and LyGenesis, Inc. announced that they have entered into a joint research collaboration to evaluate the potential of iTOL-201, the product candidate in development using iTolerance’s SA FasL microgel immune tolerance platform combined with LyGenesis’ liver cell therapy.